|
[1]
|
Liu, W., Liu, J., Song, Y., Wang, X., Zhou, M., Wang, L., et al. (2019) Mortality of Lymphoma and Myeloma in China, 2004-2017: An Observational Study. Journal of Hematology & Oncology, 12, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Wang, S., Xu, L., Feng, J., Liu, Y., Liu, L., Wang, J., et al. (2020) Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Frontiers in Oncology, 9, Article ID: 1513. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Cowan, A.J., Green, D.J., Kwok, M., Lee, S., Coffey, D.G., Holmberg, L.A., et al. (2022) Diagnosis and Management of Multiple Myeloma: A Review. JAMA, 327, 464-477. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Manohar, S., Nasr, S.H. and Leung, N. (2018) Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold. Current Hematologic Malignancy Reports, 13, 220-226. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Zuo, C., Zhu, Y. and Xu, G. (2020) An Update to the Pathogenesis for Monoclonal Gammopathy of Renal Significance. Annals of Hematology, 99, 703-714. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Sathick, I.J., Drosou, M.E. and Leung, N. (2019) Myeloma Light Chain Cast Nephropathy, a Review. Journal of Nephrology, 32, 189-198. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Vasant, J.S., Gupta, N., Malhotra, H., Godara, S., Yadav, A., Kumbhaj, P., et al. (2025) Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure. South Asian Journal of Cancer, 14, 632-635. [Google Scholar] [CrossRef]
|
|
[8]
|
Shi, M., Liu, R.R., Jin, Y.Y., et al. (2024) The Prognosis and Related Factors Impacting Renal Response in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. National Medical Journal of China, 104, 3528-3534.
|
|
[9]
|
Hughes, M.S., Balev, M., Radhakrishnan, J., Bhutani, D., Mapara, M., Lentzsch, S., et al. (2025) Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma with Modern Anti‐Myeloma Therapies. European Journal of Haematology, 114, 990-1000. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Kumar, S.K., Callander, N.S., Alsina, M., Atanackovic, D., Biermann, J.S., Chandler, J.C., et al. (2017) Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 230-269. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Inker, L.A., Schmid, C.H., Tighiouart, H., Eckfeldt, J.H., Feldman, H.I., Greene, T., et al. (2012) Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine, 367, 20-29. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Sun, Y., Zhao, J., Du, J., Li, Y., Ding, F. and Zhao, W. (2024) Clinical Implications and Predictive Value of the Creatinine‑Cystatin C Ratio in Patients with Multiple Myeloma and Renal Impairment. Oncology Letters, 27, Article No. 134. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Li, R., Wang, X., Zhao, X., Zhang, X., Chen, H., Ma, Y., et al. (2021) Cystatin C Level Is Associated with the Recovery of Renal Function in Cancer Patients after Onset of Acute Kidney Injury. Annals of Palliative Medicine, 10, 2158-2166. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Zhang, J., Jiang, Y., Guo, D., Liu, H.y., Hong, L., Qi, J., et al. (2022) The Role of Cystatin C in Multiple Myeloma. International Journal of Laboratory Hematology, 44, 135-141. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
An, L., Yin, W. and Sun, D. (2021) Albumin-to-Alkaline Phosphatase Ratio as a Promising Indicator of Prognosis in Human Cancers: Is It Possible? BMC Cancer, 21, Article No. 247. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Okamoto, S., Ureshino, H., Kidoguchi, K., Kusaba, K., Kizuka-Sano, H., Sano, H., et al. (2020) Clinical Impact of the CONUT Score in Patients with Multiple Myeloma. Annals of Hematology, 99, 113-119. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Chen, F., Liu, X., Lai, Z., Xiang, Y. and Yang, C. (2025) Association between Serum C-Reactive Protein-to-Albumin Ratio and the Prognosis of Patients with Multiple Myeloma. Indian Journal of Cancer, 62, 337-344. [Google Scholar] [CrossRef]
|
|
[19]
|
Tsai, C., Yeh, C., Hsu, T., Li, C., Tin, C., Hsiao, L., et al. (2021) Underweight as a Risk Factor of Mortality in Patients with Newly Diagnosed Multiple Myeloma. Supportive Care in Cancer, 29, 3991-3999. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Wu, T., Liu, D., Liu, S., Xiao, H., Xiong, B., Zhou, Y., et al. (2024) Chemotherapy Plus Therapeutic Plasmapheresis with 4% Human Albumin Solution in Multiple Myeloma Patients with Acute Kidney Injury: A Prospective, Open-Label, Proof-of-Concept Study. Renal Failure, 46, Article 2356708. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Nira, N.H., Akhter, S., Khan, S.R., et al. (2023) Serum Albumin and C-Reactive Protein in Hospital Admitted Patients with Chronic Kidney Disease. Mymensingh Medical Journal, 32, 307-312.
|
|
[22]
|
Leung, N. and Rajkumar, S.V. (2023) Multiple Myeloma with Acute Light Chain Cast Nephropathy. Blood Cancer Journal, 13, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Heybeli, C., De Simone, E. and Leung, N. (2025) The Role of Extracorporeal Therapy in Light Chain Cast Nephropathy. American Journal of Nephrology, 57, 223-234. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Klank, D., Löffler, C., Friedrich, J., Hoffmann, M., Paschka, P. and Bergner, R. (2024) The Urine Light Chain/EGFR Quotient as a Tool to Rule Out Cast Nephropathy in Myeloma-Associated Kidney Failure. Biomedicines, 12, Article 1032. [Google Scholar] [CrossRef] [PubMed]
|